Utah Center for Bleeding & Clotting Disorders at University of Utah Health Administers New Gene Therapy for Hemophilia B

University of Utah Health announced the successful infusion of HEMGENIX, a newly approved gene therapy for patients with severe hemophilia B—a rare bleeding disorder characterized by the inability of blood to clot properly. An estimated 33,000 males in the United States are currently living with hemophilia.

Under the direction of Dr. Ming Y. Lim, Medical Director of the Utah Center for Bleeding & Clotting Disorders and Associate Professor in the Division of Hematology and Hematologic Malignancies at the University of Utah. The team successfully secured approval and administered the therapy for a Utah resident. The infusion took place at the University of Utah Hospital, and the patient will undergo regular monitoring to ensure success of the treatment.

Though HEMGENIX is not a cure, the therapy may significantly reduce or potentially eliminate the need for weekly preventive factor infusions and spontaneous bleeding episodes.

For more information about the Utah Center for Bleeding & Clotting Disorders and its work, visit healthcare.utah.edu/bleeding-clotting-disorders